A2 cont translational modification) or mutation at residues 4, 5, 6, 7 or 8,

c) determining the immunogenicity of the peptide fragments obtained in step b), preferably by carrying out an Elispot assay.

A3 9. (Once Amended) A DNA fragment encoding at least one peptide fragment of claim 1.

A4 11. (Once Amended) A vector for expressing a peptide fragment, characterized in that said fragment comprises a sequence of at least 8 consecutive amino acids of the sequence SEQ ID No. 1, containing a DNA fragment of claim 10 fused to a promoter which is effective in eukaryotic cells and/or in prokaryotic cells, in particular in human cells.

13. (Once Amended) A vector as claimed in claim 11, characterized in that it is a viral vector, a plasmid or a pseudovector.

A5 14. (Once Amended) A dendritic cell loaded with peptide compounds as claimed in claim 1.

15. (Once Amended) A dendritic cell transformed with the expression vector as claimed in claim 11.

16. (Once Amended) A dendritic cell as claimed in claim 14, characterized in that it forms part of the macrophages.

17. (Once Amended) A pharmaceutical composition comprising a peptide compound or a mixture of peptide compounds as claimed in claim 1 and a pharmaceutically acceptable vehicle.

18. (Once Amended) A pharmaceutical composition comprising an expression vector as claimed in claim 11 and a pharmaceutically acceptable vehicle.

19. (Once Amended) A pharmaceutical composition comprising in particular a

DNA fragment as claimed in claim 9 and a pharmaceutically acceptable vehicle.

20. (Once Amended) A pharmaceutical composition comprising the cells as claimed in claim 14 and a pharmaceutically acceptable vehicle.

21. (Once Amended) A pharmaceutical composition as claimed in claim 17, characterized in that it also comprises one or more immunological adjuvants, in particular agents which are cytotoxic for tumors.

22. (Once Amended) A pharmaceutical composition as claimed in claim 17, characterized in that it comprises a pharmaceutical vehicle which is compatible with IV, subcutaneous, oral or nasal administration.

A3

23. (Once Amended) A pharmaceutical composition as claimed in claim 17, characterized in that it comprises a pharmaceutical vehicle selected from positively or negatively charged liposomes, nanoparticles or lipid emulsions.

24. (Once Amended) Use of a peptide compound as claimed in claim 1 for manufacturing a medicinal product.

25. (Once Amended) Use of a peptide compound as claimed in claim 1 for manufacturing a medicinal product intended for treating cancer.

26. (Once Amended) Use of a peptide compound as claimed in claim 1 for manufacturing a medicinal product intended for immunization ex vivo, which consists in particular in inducing tumor-specific CTLs in vitro, expanding them and reinjecting them, said induction possibly being carried out with the aid of loaded dendritic cells.

27. (Once Amended) Use of a peptide compound as claimed in claim 1 for manufacturing a medicinal product intended for immunization in vivo.

28. (Once Amended) Use of a peptide compound as claimed in claim 1 for manufacturing a medicinal product intended for the treatment of cancer, in particular solid tumors, especially carcinomas, melanomas, neuroblastomas, preferably hepatocarcinomas